Safety
GLP-1 medicines, pregnancy, and oral contraception
Pregnancy planning and contraception should be discussed before starting a GLP-1 medicine. The instructions differ by product and cannot be replaced by one class-wide rule.
Make a plan with the prescriber
Weight-management medicines are not a treatment for weight loss during pregnancy. The relevant labels advise actions when pregnancy occurs; discuss these before treatment and contact the prescriber promptly if pregnancy is suspected or recognized.
Semaglutide labels include discontinuation at least 2 months before a planned pregnancy because of its long washout period. The exact indication and clinical circumstances matter, so the clinician should coordinate diabetes or other care during a change in treatment. Do not stop all related medicines without a replacement care plan.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information
Tirzepatide and oral hormonal contraception
Mounjaro and Zepbound delay gastric emptying and can reduce oral hormonal contraceptive effectiveness. Their labels advise switching to a non-oral method or adding a barrier method for 4 weeks after initiation and for 4 weeks after every escalation.
Moving the injection to another hour does not remove the precaution. Ask which contraceptive method and backup approach fit your circumstances, and discuss vomiting or diarrhea that may affect oral medicine use.
Sources: Mounjaro prescribing information · Zepbound prescribing information
Foundayo uses different wording
Foundayo's label advises a non-oral contraceptive method or added barrier protection for 30 days after starting and for 30 days after each dose escalation. This is a separate product-specific instruction, not a reason to use tirzepatide's exact 4-week rule for every pill.
Foundayo also has medicine interactions requiring review. Bring the full medication and contraception list to the prescriber or pharmacist rather than focusing only on the weight-management prescription.
Sources: Foundayo prescribing information
Breastfeeding and restarting
Breastfeeding guidance is formulation-specific. The current Wegovy label advises against breastfeeding during tablet treatment; other products need review of their own labeling and the individual's circumstances.
After pregnancy, breastfeeding, or a prolonged interruption, discuss whether restarting is appropriate and which dose should be used. The pre-interruption dose should not be resumed automatically. This page is for planning a clinical discussion, not choosing contraception or a pregnancy treatment plan.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Foundayo prescribing information · Mounjaro prescribing information · Zepbound prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.